Loading viewer...
investor_presentation
Format: PDF investor_presentation
SONOMA PHARMACEUTICALS SECOND QUARTER FY2018 RESULTS November 9, 2017 1
SONOMA PHARMACEUTICALS
SECOND QUARTER FY2018 RESULTS
Welcome / Introduction
September 30, 2017 Highlights
Marc Umscheid Brand Building and Biz Development
Financial Review Bob Miller
2 Page Forward -Looking Statement
Except for historical information herein, matters set forth in this press release are forward -looking within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of 1995 , including statements about the commercial and
technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”) .
These forward -looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others .
Forward -looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent
applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products
will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues
will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product
formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and
other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission . The Company
disclaims any obligation to update these forward -looking statements, except as required by law.
3 Page Results from the Quarter Ended 30 September 2017
Total Net Revenue = $ 4,325,000
•Up 55% versus same period last year
•Up 13% versus quarter ended 30 Jun
4 US Dermatology Revenue = $ 1,621,000
•Up 53% versus same period last year
•Up 36% versus quarter ended 30 June 2017
EBITDA during the period = ($ 2,276,000)
Cash & cash equivalents = $9,983,000
Preview truncated — download the full document for the complete content.
investor_presentation
8 Pages
investor_presentation
59 Pages
DHL Group
Precision Drilling June 2024 Investor Presentation
investor_presentationinvestor_presentation
29 Pages
Precision Drilling Corporation